Samsung Pharm Continues Long-Term Administration of PSP Treatment GV1001... Expanding Patient Access to Therapy
On March 26, Samsung Pharm announced that patients who participated in the clinical trial of the progressive supranuclear palsy (PSP) treatment "GV1001" are continuing to receive additional doses in a stable manner through the Korea Ministry of Food and Drug Safety’s compassionate use program.
The compassionate use program allows the use of investigational drugs for treatment purposes when patients are suffering from life-threatening, severe diseases or have no alternative treatment options available.
This case was initially conducted by GemVax & KAEL under approval from the Korea Ministry of Food and Drug Safety for between two and fewer than 25 patients. Recently, the sponsor for this program has changed to Samsung Pharm.
According to the company, all 24 patients eligible for registration through the compassionate use program have completed participation. Most of these patients have now maintained long-term treatment for more than two years, including the previous 18-month clinical trial period.
Progressive supranuclear palsy is a rare disease with an average survival period of only about 6 to 7 years, and currently, there is no definitive treatment available.
A Samsung Pharm representative stated, "It is highly significant that PSP patients have been able to continue treatment stably for more than two years," adding, "We will continue to support uninterrupted treatment and steadily advance follow-up clinical trials to provide more patients with real therapeutic opportunities."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Samsung Pharm has recently secured the rights to clinical development and commercialization of GV1001 in four major Asian countries, including Korea, through a technology transfer agreement with GemVax. The company has also applied for conditional product approval from the Korea Ministry of Food and Drug Safety.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.